RemeGen IPO: Valuation Insights
RemeGen has launched a Hong Kong IPO to raise net proceeds of HK$3,710.5 million ($479 million). Overall, a strong cornerstone lineup and our...
440 Views
RemeGen IPO: Key Drugs Show Promising Potential
RemeGen is a commercial-ready biopharmaceutical company who has filed for an IPO on the HKEX. In this insight, we explore the company's core drug...
318 Views
RemeGen (荣昌生物) IPO: Pricing the R&D Leadership
RemeGen is a China-based commercial-ready biopharmaceutical company with a focus on first-in-class and best-in-class biologics in the area of...
398 Views
RemeGen IPO Initiation: Seeking a Cure
RemeGen currently has a pipeline of more than ten drug candidates. Overall, we believe that the prospectus RemeGen’s core drug assets (telitacept,...
301 Views
Pre-IPO RemeGen - Insights on Two Core Products RC18 & RC48
This article analyzed two core products from RemeGen: RC18 and RC 48. The commercialization of these two products would have direct impact on the...
414 Views